These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Photooxidation of troglitazone, a new antidiabetic drug. Fu Y; Sheu C; Fujita T; Foote CS Photochem Photobiol; 1996 May; 63(5):615-20. PubMed ID: 8628753 [TBL] [Abstract][Full Text] [Related]
4. Physicochemical and crystal structure analyses of the antidiabetic agent troglitazone. Kobayashi K; Fukuhara H; Hata T; Sekine A; Uekusa H; Ohashi Y Chem Pharm Bull (Tokyo); 2003 Jul; 51(7):807-14. PubMed ID: 12843587 [TBL] [Abstract][Full Text] [Related]
5. Structural studies on the impurities of troglitazone. Moses Babu J; Nageshwar D; Ravindra Kumar Y; Prabhakar C; Sarma MR; Om Reddy G; Vyas K J Pharm Biomed Anal; 2003 Feb; 31(2):271-81. PubMed ID: 12609666 [TBL] [Abstract][Full Text] [Related]
6. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045. Yoshioka T; Aizawa Y; Fujita T; Nakamura K; Sasahara K; Kuwano H; Kinoshita T; Horikoshi H Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2124-5. PubMed ID: 1797433 [TBL] [Abstract][Full Text] [Related]
7. Physical property of troglitazone, an equal mixture of four stereoisomers. Suzuki N; Kasahara K; Hasegawa H; Kawasaki T Int J Pharm; 2002 Nov; 248(1-2):71-80. PubMed ID: 12429461 [TBL] [Abstract][Full Text] [Related]
8. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Johnson MD; Campbell LK; Campbell RK Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065 [TBL] [Abstract][Full Text] [Related]
9. Solid-state variation of troglitazone drug substance by using a different recrystallization method. Suzuki N; Kasahara K; Watanabe Y; Kinoshita S; Hasegawa H; Kawasaki T Drug Dev Ind Pharm; 2003 Aug; 29(7):805-12. PubMed ID: 12906338 [TBL] [Abstract][Full Text] [Related]
10. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Baillie TA; Kassahun K Adv Exp Med Biol; 2001; 500():45-51. PubMed ID: 11764978 [No Abstract] [Full Text] [Related]
11. Reduction of vascular tone by introduction of troglitazone to the canine coronary artery. Osanai H; Toki Y; Nakashima Y; Okumura K; Ito T; Hayakawa T Arzneimittelforschung; 1999 Jan; 49(1):26-9. PubMed ID: 10028375 [TBL] [Abstract][Full Text] [Related]
12. A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance. Cossy J; Menciu C; Rakotoarisoa H; Kahn PH; Desmurs JR Bioorg Med Chem Lett; 1999 Dec; 9(24):3439-40. PubMed ID: 10617087 [TBL] [Abstract][Full Text] [Related]
13. Direct chiral separation of troglitazone stereoisomers using reversed-phase high-performance liquid chromatography. Suzuki N; Takemura A; Miyamoto A; Yoshioka T; Tsutsumi S; Kawasaki T J Pharm Biomed Anal; 2002 Oct; 30(3):823-36. PubMed ID: 12367708 [TBL] [Abstract][Full Text] [Related]
14. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Masuda K; Okamoto Y; Tsuura Y; Kato S; Miura T; Tsuda K; Horikoshi H; Ishida H; Seino Y Diabetologia; 1995 Jan; 38(1):24-30. PubMed ID: 7744225 [TBL] [Abstract][Full Text] [Related]
15. Troglitazone (CS-045): a new antidiabetic agent. Kaneko T Horm Metab Res; 1997 May; 29(5):203-13. PubMed ID: 9228204 [No Abstract] [Full Text] [Related]